Medtronic Plc (MDT), a key player in the biotech market, has experienced a mix of gains and losses. The firm demonstrated strong revenue and EPS growth in Q2 2025, despite a market downturn that saw the company's stock decline by 5.6%. Truist Financial has lowered expectations for MDT's share price, implying potential undervaluation. Several investment groups, including Tudor Financial and TCW Group have acquired substantial shares, signifying the firm's appeal to institutional investors. Despite experiencing seven sessions of losses, the firm continues to get positive attention, being part of Ken Griffin's portfolio and is recognized as a leading medical device company amidst market challenges. BlackRock identified MDT as a significant AI stock, while multiple sources consider it a top value stock for the long term. The past five years have not been profitable for MDT investors. MDT's share saw slight fluctuations, with trading up to 0.6% and down to 0.5%. However, Jim Cramer continues to endorse the medical giant, citing it as a 'winner'.
Medtronic Plc MDT News Analytics from Thu, 09 May 2024 07:00:00 GMT to Fri, 20 Dec 2024 21:06:08 GMT -
Rating 5
- Innovation 8
- Information 8
- Rumor 2
